Detailed Information on Publication Record
2015
Expression of VEGF-A by neoplastic cells in T-cell lymphoblastic lymphoma: possible therapeutic implications related to immunomodulatory properties of this cytokine
KŘENOVÁ, Zdenka, Jaroslav ŠTĚRBA, Eliška TVRDÍKOVÁ and Leoš KŘENBasic information
Original name
Expression of VEGF-A by neoplastic cells in T-cell lymphoblastic lymphoma: possible therapeutic implications related to immunomodulatory properties of this cytokine
Authors
KŘENOVÁ, Zdenka (203 Czech Republic, guarantor, belonging to the institution), Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution), Eliška TVRDÍKOVÁ (203 Czech Republic, belonging to the institution) and Leoš KŘEN (203 Czech Republic, belonging to the institution)
Edition
Fifth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, 2015
Other information
Language
English
Type of outcome
Konferenční abstrakt
Field of Study
30200 3.2 Clinical medicine
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 5.812
RIV identification code
RIV/00216224:14110/15:00085103
Organization unit
Faculty of Medicine
ISSN
Keywords in English
T-cell lymphoblastic lymphoma
Tags
Změněno: 7/12/2015 14:44, Ing. Mgr. Věra Pospíšilíková
Abstract
V originále
Background: VEGF-A, well known for its mechanistic angiogenic effect and as a target for antiangiogenic therapeutic drugs, has also potent immunomodulatory characteristics. Namely, it contributes to blockade of dendritic cells maturation and increases a number of regulatory T lymphocytes (Treg’s) in blood and tumor tissues. Conclusion: We found expression of VEGF-A in a majority of cases of T-LL. Because of known immunosuppressive properties of VEGFA, possible adding of antiangiogenic drugs to therapeutic armamentarium in T-LL appears warranted.